Last updated: November 3, 2026
Vericiguat, marketed as Verquvo by Bayer and Merck, is an oral soluble guanylate cyclase stimulator for adults with symptomatic chronic heart failure and reduced ejection fraction who recently experienced worsening heart failure. Its commercial opportunity is concentrated in a high-mortality population with recurrent hospitalizations, but uptake has been constrained by a narrow labeled population, competition from established guideline-directed therapies, and the rapid expansion of SGLT2 inhibitors.
Bayer has reported steady post-launch growth, but Verquvo remains a mid-sized pharmaceutical asset rather than a near-term multibillion-euro product. Its financial value depends on broader use across the eligible heart-failure population, evidence of benefit in less-selected patients, international reimbursement, and the timing of generic entry.
What is vericiguat and how does Verquvo work?
Vericiguat activates soluble guanylate cyclase, increasing cyclic guanosine monophosphate signaling. The mechanism is intended to address impaired nitric oxide-sGC signaling associated with heart failure and vascular dysfunction.
The FDA approved Verquvo in January 2021 for adults with symptomatic chronic heart failure and ejection fraction below 45% who had experienced a recent worsening event requiring hospitalization or outpatient intravenous diuretics. The treatment is used to reduce the risk of cardiovascular death and hospitalization for heart failure.[1]
| Attribute |
Verquvo |
| Active ingredient |
Vericiguat |
| Brand owner and commercial partners |
Bayer and Merck & Co. |
| Drug class |
Soluble guanylate cyclase stimulator |
| Route |
Oral |
| Standard target dose |
10 mg once daily after titration |
| Initial FDA approval |
January 2021 |
| Core indication |
Symptomatic chronic heart failure with reduced ejection fraction after recent worsening |
| Key trial |
VICTORIA |
| Trial population |
5,050 patients |
| Primary endpoint |
Composite of cardiovascular death or first heart-failure hospitalization |
The European Commission authorized vericiguat in 2021 for adults with symptomatic chronic heart failure and reduced ejection fraction who had stabilized after a recent decompensation event.[2]
How effective is vericiguat in heart failure?
The VICTORIA trial produced a statistically significant reduction in the composite primary endpoint, but the clinical effect was modest when compared with the size of benefit reported for some newer heart-failure therapies.
In VICTORIA, the composite of cardiovascular death or first heart-failure hospitalization occurred in 35.5% of patients receiving vericiguat and 38.5% of patients receiving placebo. The hazard ratio was 0.90, with a 95% confidence interval of 0.82 to 0.98.[3]
The trial had several characteristics that shaped the commercial market:
- Patients had recently worsened, creating a higher-risk population than many earlier heart-failure studies.
- Median NT-proBNP levels were high, reflecting advanced disease.
- The mortality component alone did not produce a statistically significant reduction.
- The primary benefit was driven largely by fewer heart-failure hospitalizations.
- Patients received substantial background therapy, including beta blockers, renin-angiotensin system inhibitors, mineralocorticoid receptor antagonists and, in some cases, sacubitril/valsartan.
The result positioned Verquvo as an add-on treatment for patients who remain at high risk after a worsening event, rather than as a universal first-line therapy for all patients with reduced-ejection-fraction heart failure.
What is the commercial market for vericiguat?
The addressable market is large in epidemiological terms but narrower in labeled-treatment terms. Heart failure affects millions of patients in the United States and Europe, yet Verquvo is aimed primarily at patients with reduced ejection fraction who have recently decompensated.
Commercial adoption depends on five factors:
- Identification of patients after hospitalization or outpatient intravenous diuretic treatment.
- Initiation before discharge or shortly after stabilization.
- Reimbursement for an add-on therapy in patients already receiving multiple medicines.
- Physician confidence that the hospitalization benefit justifies another chronic prescription.
- Ability to differentiate Verquvo from SGLT2 inhibitors and sacubitril/valsartan.
The strongest commercial setting is the post-discharge transition period. Patients with recurrent hospitalizations, persistent congestion, renal impairment or advanced symptoms represent the most logical target population.
The main market constraint is treatment sequencing. Clinicians often prioritize four foundational therapies for heart failure with reduced ejection fraction:
- An angiotensin receptor-neprilysin inhibitor, ACE inhibitor or angiotensin receptor blocker.
- A beta blocker.
- A mineralocorticoid receptor antagonist.
- An SGLT2 inhibitor.
Vericiguat is generally considered after, or alongside, these therapies. That positioning reduces the number of patients for whom it is viewed as an immediate treatment priority.
What is the financial trajectory for Verquvo?
Verquvo has followed a typical specialty-launch pattern: limited initial revenue during the launch period, followed by expansion as reimbursement, hospital protocols and physician familiarity developed.
Bayer has reported Verquvo as part of its pharmaceutical portfolio and has identified the product as one of its newer growth assets. Public reporting shows a materially smaller revenue base than Bayer's leading products, including Xarelto, Eylea, Nubeqa and Kerendia.[4]
| Financial driver |
Effect on Verquvo |
| 2021 FDA and European launches |
Established initial commercial base |
| Post-discharge treatment setting |
Supports targeted adoption |
| High generic competition in background therapy |
Limits total prescription value |
| SGLT2 inhibitor expansion |
Creates prescribing competition |
| Bayer-Merck commercialization |
Broadens geographic reach |
| Narrow eligible population |
Caps peak sales potential |
| Hospitalization reduction |
Supports payer value arguments |
| No biologic manufacturing burden |
Lowers production complexity |
Verquvo's financial trajectory is more consistent with a durable specialty product than with a near-term blockbuster. Bayer's portfolio strategy has placed greater emphasis on products with larger expansion opportunities, particularly oncology and kidney disease assets. Verquvo contributes recurring revenue and cardiovascular diversification, but it does not carry the same growth profile as Nubeqa or Kerendia.
Merck's public reporting does not provide a consistently detailed standalone revenue series for Verquvo. The collaboration is therefore more transparent through Bayer's pharmaceutical reporting than through Merck's consolidated disclosures.[5]
What determines Verquvo peak sales?
Peak sales depend on the proportion of eligible patients treated after a worsening heart-failure event. The product has a credible path to growth if it becomes embedded in discharge protocols and cardiology treatment pathways.
The commercial ceiling is lower if physicians reserve Verquvo for only the sickest patients. That approach produces good treatment intensity but a limited number of prescriptions. Broader use would require evidence that the therapy provides meaningful incremental value when combined with modern SGLT2 inhibitor-based treatment.
Pricing is also important. As an oral small molecule with no complex administration requirements, Verquvo does not command the same pricing logic as specialty biologics or gene therapies. Payers are likely to evaluate it against hospitalization savings, particularly in high-risk patients.
How does Verquvo compare with competing heart-failure drugs?
Verquvo competes in a crowded treatment environment rather than against a single direct substitute.
| Therapy |
Primary commercial position |
Key competitive effect on Verquvo |
| Sacubitril/valsartan |
Foundational therapy for reduced-ejection-fraction heart failure |
Often prioritized before vericiguat |
| Dapagliflozin and empagliflozin |
SGLT2 inhibitors used across broad heart-failure populations |
Have broader labels and strong guideline momentum |
| Spironolactone and finerenone |
Mineralocorticoid pathway therapies |
Compete for treatment sequencing and budget |
| Ivabradine |
Heart-rate reduction in selected patients |
Smaller overlapping population |
| Digoxin |
Low-cost historical option |
Limits willingness to pay in some markets |
| Vericiguat |
Add-on therapy after recent worsening |
Most differentiated in high-risk post-decompensation patients |
SGLT2 inhibitors represent the strongest strategic pressure. Their clinical use extends across multiple heart-failure phenotypes, including patients with preserved or mildly reduced ejection fraction. Vericiguat has a narrower indication and a more event-driven treatment pathway.
Verquvo's counter-position is its VICTORIA evidence in patients who have recently worsened. The product is most competitive when the physician is addressing residual risk after a hospitalization, rather than initiating broad chronic heart-failure therapy.
What patents protect vericiguat and when could generic entry occur?
Vericiguat is a small molecule, so it faces ordinary generic, rather than biosimilar, competition. The relevant intellectual-property estate includes composition-of-matter claims, pharmaceutical compositions, dosing claims and possible method-of-use claims.
The core United States patent estate has included patents covering substituted pyrazole compounds and related pharmaceutical compositions. Patent term and regulatory exclusivity depend on the specific patent, pediatric extensions and any patent-term adjustment. Orange Book-listed patents, rather than the basic approval date, determine the principal U.S. generic-entry risk.[6]
| Protection category |
Commercial relevance |
| Composition-of-matter patents |
Usually the strongest barrier to an ANDA |
| Pharmaceutical-composition patents |
May protect tablets, excipients or dosage forms |
| Dose and titration claims |
Can create additional litigation exposure |
| Method-of-use patents |
May cover treatment of specific heart-failure populations |
| Regulatory exclusivity |
Provides a separate, time-limited FDA barrier |
| Manufacturing patents |
May complicate supply but rarely prevent all generic entry |
The principal risk window is likely to emerge in the late 2020s or early 2030s, depending on the enforceability and expiration of the relevant patent claims. A generic applicant could file an Abbreviated New Drug Application with a Paragraph IV certification against an Orange Book patent before expiration. That filing could trigger patent litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman Act.[7]
No biosimilar pathway applies because vericiguat is a chemically synthesized small molecule. The relevant competitive event is an ANDA-based generic launch.
What is the Orange Book status of Verquvo?
The FDA Orange Book is the controlling source for listed U.S. patents and exclusivity information. Verquvo's commercial protection should be assessed by reviewing:
- Listed composition patents.
- Listed formulation or dosage-form patents.
- Any method-of-use patents.
- Patent expiration dates after patent-term adjustment.
- Pediatric exclusivity.
- The status of any Paragraph IV notices or ANDA litigation.
An Orange Book listing does not guarantee that every patent will block generic approval. A generic applicant can challenge validity, enforceability or infringement. Conversely, a patent not listed in the Orange Book may still create litigation or manufacturing risk, but it generally has less direct effect on FDA approval timing.
Which companies could challenge Verquvo?
The most likely challengers are large generic manufacturers with cardiovascular portfolios and the ability to litigate Hatch-Waxman cases. Potential participants include Teva, Sandoz, Viatris, Sun Pharma, Dr. Reddy's Laboratories, Cipla and other ANDA sponsors.
The commercial attractiveness of a challenge depends on:
- Expected market size at first generic launch.
- Number of eligible patients receiving therapy.
- The strength and remaining life of composition patents.
- The cost of Paragraph IV litigation.
- Whether multiple generic applicants file in the same period.
- Whether the branded companies offer a settlement involving a licensed entry date.
Publicly reported generic litigation and settlement activity should be monitored through FDA Orange Book updates, federal court dockets and company filings. A first-filer Paragraph IV position could create a period of 180-day generic exclusivity, although the commercial value would depend on the size of the remaining branded market.
How strong is the Verquvo patent estate?
The estate is strongest if a valid composition-of-matter patent remains enforceable through the period when Verquvo generates meaningful revenue. Formulation and dosing patents are usually less durable because generic applicants can sometimes design around them or challenge their validity.
The commercial patent assessment should weigh:
- Remaining patent life.
- Claim breadth.
- Prior-art exposure.
- Orange Book listing status.
- Patent-term adjustment or extension.
- Evidence of design-around options.
- The number and sophistication of potential ANDA filers.
Verquvo's patent risk is therefore more timing-sensitive than technology-sensitive. The drug does not require a complex delivery system, device or biologic manufacturing process that would create a substantial technical barrier to generic replication.
What regulatory and clinical events could change the market?
The most important upside event would be a label expansion or new evidence supporting use earlier in the treatment sequence. Evidence showing incremental benefit alongside contemporary SGLT2 inhibitor therapy could broaden adoption.
Potential downside events include:
- Weak uptake outside specialist cardiology.
- Payer restrictions on add-on use.
- Generic entry before the product reaches a larger revenue base.
- New heart-failure agents with broader indications.
- Clinical evidence showing limited incremental benefit in routine practice.
- Failure to demonstrate benefit in less-selected heart-failure populations.
The product's regulatory risk is lower than its commercial execution risk. FDA approval is established, and the principal question is whether the market will accept Verquvo as a routine post-worsening therapy.
What generic launch scenarios exist for Verquvo?
Scenario 1: Protected specialty product
If the key composition claims remain enforceable and no successful Paragraph IV challenge occurs, Verquvo can maintain branded pricing until the relevant patent barrier expires. Revenue would likely depend on gradual penetration rather than rapid expansion.
Scenario 2: Settlement-based entry
Bayer and Merck could resolve litigation through an agreement permitting a generic launch before full patent expiry. The entry date, authorized generic terms and number of licensees would determine the revenue impact.
Scenario 3: Early invalidation or non-infringement finding
A successful Paragraph IV challenge could produce an earlier generic launch and a sharp decline in price and branded volume. Cardiovascular small molecules generally experience substantial erosion once multiple generic suppliers enter.
Scenario 4: Authorized generic competition
An authorized generic could moderate the impact on total franchise economics while reducing the price advantage of independent ANDA entrants. The effect would depend on licensing terms and the timing of launch.
Key Takeaways
- Vericiguat is a targeted add-on therapy for high-risk heart-failure patients after recent worsening.
- VICTORIA demonstrated a 10% relative reduction in the composite of cardiovascular death or first heart-failure hospitalization, driven mainly by hospitalization reduction.
- The product competes with broader, heavily adopted therapies, especially SGLT2 inhibitors.
- Bayer has reported continued commercial growth, but Verquvo remains a mid-sized asset rather than a leading portfolio product.
- Its best commercial opportunity is in post-discharge protocols and patients with recurrent decompensation.
- Generic competition will arrive through the ANDA and Paragraph IV pathway, not through biosimilar substitution.
- Composition-of-matter protection is the central determinant of launch timing; formulation and method-of-use patents provide secondary protection.
- Revenue risk rises materially once multiple generic manufacturers enter because the product is an oral small molecule without complex manufacturing barriers.
FAQs
Is vericiguat a blockbuster drug?
No. Vericiguat has commercial value as a specialty cardiovascular product, but its narrow indication, add-on positioning and competition from SGLT2 inhibitors limit its probability of reaching blockbuster scale.
Is Verquvo better than Jardiance or Farxiga for heart failure?
The therapies occupy different positions. Jardiance and Farxiga have broader heart-failure use and strong guideline adoption, while Verquvo is targeted toward patients with reduced ejection fraction who recently experienced worsening heart failure.
Does vericiguat reduce mortality?
The VICTORIA trial reduced the composite of cardiovascular death or first heart-failure hospitalization. The mortality component alone did not show a statistically significant reduction.
Can patients take vericiguat with an SGLT2 inhibitor?
Vericiguat can be used with standard heart-failure therapies, subject to the prescribing information and clinical judgment. The commercial question is whether its incremental benefit remains sufficiently meaningful when patients already receive contemporary background therapy.
What type of generic competition will Verquvo face?
Verquvo will face chemically equivalent generic vericiguat products filed through the FDA's ANDA pathway. Paragraph IV patent challenges are the principal mechanism for seeking approval before listed patent expiration.
References
- U.S. Food and Drug Administration. (2021). Verquvo prescribing information.
- European Medicines Agency. (2021). Verquvo: EPAR - product information.
- Armstrong, P. W., Pieske, B., Anker, S. D., et al. (2020). Vericiguat in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 382(20), 1883-1893.
- Bayer AG. (2021-2023). Annual reports and quarterly financial reports.
- Merck & Co., Inc. (2021-2023). Annual reports and financial results.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984.
